Connecticut Wealth Management LLC Has $957,000 Holdings in Edwards Lifesciences Co. (NYSE:EW)

Connecticut Wealth Management LLC lifted its holdings in Edwards Lifesciences Co. (NYSE:EW) by 26.0% during the 4th quarter, HoldingsChannel reports. The fund owned 12,549 shares of the medical research company’s stock after acquiring an additional 2,589 shares during the quarter. Connecticut Wealth Management LLC’s holdings in Edwards Lifesciences were worth $957,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. National Bank of Canada FI grew its stake in shares of Edwards Lifesciences by 4.6% in the fourth quarter. National Bank of Canada FI now owns 214,861 shares of the medical research company’s stock valued at $16,234,000 after acquiring an additional 9,352 shares in the last quarter. Vestmark Advisory Solutions Inc. lifted its holdings in shares of Edwards Lifesciences by 13.1% during the 4th quarter. Vestmark Advisory Solutions Inc. now owns 6,834 shares of the medical research company’s stock worth $521,000 after acquiring an additional 793 shares during the period. Baxter Bros Inc. boosted its position in shares of Edwards Lifesciences by 7.1% during the 4th quarter. Baxter Bros Inc. now owns 90,542 shares of the medical research company’s stock worth $6,904,000 after acquiring an additional 5,985 shares in the last quarter. Malaga Cove Capital LLC increased its stake in Edwards Lifesciences by 43.0% in the fourth quarter. Malaga Cove Capital LLC now owns 6,907 shares of the medical research company’s stock valued at $527,000 after acquiring an additional 2,076 shares during the last quarter. Finally, 9258 Wealth Management LLC raised its position in Edwards Lifesciences by 24.8% during the fourth quarter. 9258 Wealth Management LLC now owns 10,529 shares of the medical research company’s stock valued at $803,000 after purchasing an additional 2,093 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Up 0.2 %

Shares of NYSE:EW traded up $0.19 during mid-day trading on Friday, hitting $85.25. The company had a trading volume of 2,327,197 shares, compared to its average volume of 3,001,614. The firm has a fifty day moving average price of $90.08 and a 200 day moving average price of $79.46. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. The company has a market capitalization of $51.37 billion, a PE ratio of 36.75, a price-to-earnings-growth ratio of 3.59 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.02. The business had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. As a group, research analysts forecast that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Royal Bank of Canada lifted their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a report on Monday, April 15th. Evercore ISI cut their price objective on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a report on Friday, April 26th. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. Citigroup lifted their price target on Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. Finally, StockNews.com upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Monday, April 29th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $92.71.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total value of $1,212,624.00. Following the completion of the transaction, the vice president now owns 173,849 shares in the company, valued at approximately $14,639,824.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $86.67, for a total value of $2,543,764.50. Following the sale, the director now owns 4,486 shares of the company’s stock, valued at approximately $388,801.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total value of $1,212,624.00. Following the transaction, the vice president now directly owns 173,849 shares of the company’s stock, valued at $14,639,824.29. The disclosure for this sale can be found here. Insiders have sold 237,749 shares of company stock worth $20,920,934 in the last 90 days. Insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.